Rani Therapeutics Holdings, Inc. (RANI) — 8-K Filings

8-K Filings (16)

• Rani Therapeutics Appoints New Director, Board Changes — Oct 27, 2025 Risk: low
  Rani Therapeutics Holdings, Inc. announced on October 22, 2025, a change in its board of directors. Specifically, Dr. David S. Leo has been appointed as a new d
• Rani Therapeutics Files 8-K on Key Agreements and Sales — Oct 17, 2025 Risk: medium
  Rani Therapeutics Holdings, Inc. filed an 8-K on October 17, 2025, reporting on events occurring on October 16, 2025. The filing indicates the entry into a mate
• Rani Therapeutics Files 8-K: Other Events & Exhibits — Jul 16, 2025 Risk: low
  On July 14, 2025, Rani Therapeutics Holdings, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," in
• Rani Therapeutics Faces Delisting Concerns — Jun 26, 2025 Risk: high
  Rani Therapeutics Holdings, Inc. filed an 8-K on June 26, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and
• Rani Therapeutics Files 8-K on Shareholder Vote Matters — May 29, 2025 Risk: low
  Rani Therapeutics Holdings, Inc. filed an 8-K on May 29, 2025, reporting on matters submitted to a vote of security holders as of May 28, 2025. The filing detai
• Rani Therapeutics Files 8-K: Agreements & Equity Sales — May 20, 2025 Risk: medium
  On May 20, 2025, Rani Therapeutics Holdings, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The
• Rani Therapeutics Faces Delisting Notice — May 6, 2025 Risk: high
  Rani Therapeutics Holdings, Inc. filed an 8-K on May 6, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a
• Rani Therapeutics Files 8-K on Officer/Director Changes — Apr 30, 2025 Risk: medium
  Rani Therapeutics Holdings, Inc. filed an 8-K on April 30, 2025, reporting events as of April 24, 2025. The filing indicates changes related to the departure of
• Rani Therapeutics Appoints PricewaterhouseCoopers as New Auditor — Apr 9, 2025 Risk: low
  Rani Therapeutics Holdings, Inc. announced on April 7, 2025, a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its
• Rani Therapeutics Files 8-K — Oct 16, 2024 Risk: low
  Rani Therapeutics Holdings, Inc. filed an 8-K on October 15, 2024, reporting other events and financial statements. The filing details the company's corporate i
• Rani Therapeutics Changes Auditors — Sep 11, 2024 Risk: medium
  Rani Therapeutics Holdings, Inc. announced on September 10, 2024, a change in its principal accounting firm. The company has dismissed PricewaterhouseCoopers LL
• Rani Therapeutics Files 8-K — Jul 23, 2024 Risk: low
  Rani Therapeutics Holdings, Inc. filed an 8-K on July 23, 2024, reporting an event that occurred on July 22, 2024. The filing is categorized under 'Other Events
• Rani Therapeutics Files 8-K for Regulation FD Disclosure — Jul 12, 2024 Risk: low
  Rani Therapeutics Holdings, Inc. filed an 8-K on July 12, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nat
• Rani Therapeutics Enters Material Definitive Agreement — Jun 24, 2024 Risk: medium
  Rani Therapeutics Holdings, Inc. announced on June 17, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details
• Rani Therapeutics Files 8-K on Shareholder Votes — May 30, 2024 Risk: low
  Rani Therapeutics Holdings, Inc. filed an 8-K on May 30, 2024, reporting on matters submitted to a vote of security holders as of May 29, 2024. The filing detai
• Rani Therapeutics Confirms Nasdaq Listing for Class A Common Stock — Feb 5, 2024
  Rani Therapeutics Holdings, Inc. filed an 8-K on February 5, 2024, to disclose that its Class A common stock, with a par value of $0.0001 per share, is register

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX